-->

Tag: HNSCC

Home / HNSCC

Categories

Neoadjuvant and adjuvant pembrolizumab is approved by the USFDA for resectable locally advanced head and neck squamous cell carcinoma

On June 12, 2025, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for adults with advanced head and neck squamous cell carcinoma (HNSCC) that can be surgically removed and sh...
hnscc

Pabosini plus cetuximab for head and neck cancer treatment with 70% focal reduction

According to the results announced at the 2018 ASCO annual meeting, the CDK4/6 inhibitors pabociclib (Ibrance) and cetuximab (Erbitux) combined treatment of platinum-resistant and HPV-independent  re...
hnscc

Scan the code